COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
Top Cited Papers
Open Access
- 23 July 2020
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 136 (4), 489-500
- https://doi.org/10.1182/blood.2020006520
Abstract
Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter retrospective study describes the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively. Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization (D-dimer >2500 ng/mL, adjusted odds ratio [OR] for thrombosis, 6.79 [95% CI, 2.39-19.30]; adjusted OR for bleeding, 3.56 [95% CI, 1.01-12.66]), critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450 × 109/L (adjusted OR, 3.56 [95% CI, 1.27-9.97]), C-reactive protein (CRP) >100 mg/L (adjusted OR, 2.71 [95% CI, 1.26-5.86]), and erythrocyte sedimentation rate (ESR) >40 mm/h (adjusted OR, 2.64 [95% CI, 1.07-6.51]). ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than in those without. DIC, clinically relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.Keywords
This publication has 22 references indexed in Scilit:
- The cumulative venous thromboembolism incidence and risk factors in intensive care patients receiving the guideline-recommended thromboprophylaxisMedicine, 2019
- C-reactive protein and risk of venous thromboembolism: results from a population-based case-crossover studyHaematologica, 2018
- Platelet Transfusion: A Clinical Practice Guideline From the AABBAnnals of Internal Medicine, 2015
- Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxisIntensive Care Medicine, 2013
- The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5‐year overviewJournal of Thrombosis and Haemostasis, 2007
- D-dimer Correlates With Proinflammatory Cytokine Levels and Outcomes in Critically Ill PatientsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2002
- Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.2001
- Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular CoagulationThrombosis and Haemostasis, 2001
- The perils of D-dimer in the medical intensive care unitCritical Care Medicine, 2000
- Reporting results of cancer treatmentCancer, 1981